
Bigfoot Biomedical is a medical device company changing diabetes care for people with insulin-requiring diabetes. The company developing an end-to-end type 1 diabetes management system using a simple design, cloud connectivity, and human-centered automation. It optimizes the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care. Biofoot Biomedical ’s pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. By employing data-driven intelligence across an integrated device ecosystem, they are transforming diabetes care with a fully comprehensive digital drug delivery platform experienced as a service.

Bigfoot Biomedical is a medical device company changing diabetes care for people with insulin-requiring diabetes. The company developing an end-to-end type 1 diabetes management system using a simple design, cloud connectivity, and human-centered automation. It optimizes the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care. Biofoot Biomedical ’s pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. By employing data-driven intelligence across an integrated device ecosystem, they are transforming diabetes care with a fully comprehensive digital drug delivery platform experienced as a service.
Product: Bigfoot Unity connected insulin management system (integrates CGM, apps, injection/infusion support)
Founded: 2014
Headquarters: Milpitas, California
Total funding (reported): USD 204,630,000
Acquisition: Acquired by Abbott (announcement in 2023)
Type 1 and insulin-requiring diabetes management; insulin dosing and delivery optimization.
2014
Medical devices / Digital health
USD 35,500,000
Participation from Cormorant Asset Management, Senvest Capital, and Visionnaire Ventures
USD 37,000,000
Included participation from existing investors
USD 55,000,000
New investment from Abbott and participation from prior investors
Latest reported financing round listed as a Convertible Note
“Participation from strategic and institutional investors including Quadrant-advised entities, Janus Henderson-managed funds, Cormorant Asset Management, and Abbott”